» Articles » PMID: 9885781

Long-lasting Psychotomimetic Consequences of Repeated Low-dose Amphetamine Exposure in Rhesus Monkeys

Overview
Date 1999 Jan 14
PMID 9885781
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

The dopamine hypothesis of schizophrenia posits that dopamine dysregulation plays a key role in the etiology of schizophrenia. In line with this hypothesis, repeated amphetamine (AMPH) exposure has been shown to alter dopamine systems and induce behaviors reminiscent of positive-like and negative-like symptoms in both human and nonhuman primates. The mechanisms by which AMPH produces disturbances in brain function and behavior are not fully understood. The present study has employed a novel AMPH regimen, 12 weeks of intermittent escalating low doses of AMPH, to produce a nonhuman primate model for the purpose of elucidating the behavioral and neural consequences of excessive dopamine exposure. Behavioral responses to acute AMPH challenge (0.4-0.46 mg/kg) were assessed prior to and following the chronic 12-week treatment regimen, and, at present monkeys have been followed out to 28 months post-treatment. After chronic treatment, enhanced behavioral responses to AMPH challenge were readily apparent at 5 days postwithdrawal, and, were still present at 28 months postwithdrawal. The enhanced behavioral responses to low-dose AMPH challenge that were observed in the present study resemble closely the behavioral profile that has been described for chronic high-dose AMPH treatment in monkeys; i.e., hallucinatory-like behaviors, static posturing, and fine-motor stereotypies were all exacerbated in response to AMPH injection. In some animals, acute challenges after chronic AMPH evoked aberrant behavioral responses that lasted for 4 days. AMPH-treated monkeys also exhibited a significant decrease in the incidence of motor stereotypies in the off-drug periods between challenges. The present results are the first to document persistent long-term behavioral effects of intermittent exposure to repeated low-dose AMPH treatment in nonhuman primates. These findings may lay the groundwork for the development of a primate mode of psychosis with possible positive-like and negative-like symptoms.

Citing Articles

Reevaluating ADHD and its First-Line Treatment: Insights from DSM-5-TR and Modern Approaches.

Ophir Y Clin Neuropsychiatry. 2024; 21(5):436-443.

PMID: 39540077 PMC: 11555658. DOI: 10.36131/cnfioritieditore20240507.


Does stimulant drug-induced sensitization occur in primates?.

Leyton M J Psychiatry Neurosci. 2022; 47(2):E148-E152.

PMID: 35418507 PMC: 9259430. DOI: 10.1503/jpn.220055.


Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.

Iskhakova L, Rappel P, Deffains M, Fonar G, Marmor O, Paz R Nat Commun. 2021; 12(1):7026.

PMID: 34857767 PMC: 8640051. DOI: 10.1038/s41467-021-27375-5.


What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications.

Framer A Ther Adv Psychopharmacol. 2021; 11:2045125321991274.

PMID: 33796265 PMC: 7970174. DOI: 10.1177/2045125321991274.


Cued for risk: Evidence for an incentive sensitization framework to explain the interplay between stress and anxiety, substance abuse, and reward uncertainty in disordered gambling behavior.

Hellberg S, Russell T, Robinson M Cogn Affect Behav Neurosci. 2018; 19(3):737-758.

PMID: 30357661 PMC: 6482104. DOI: 10.3758/s13415-018-00662-3.